

REGISTERED COMPANY NUMBER: 06996068 (England and Wales)
REGISTERED CHARITY NUMBER: 1132984

REPORT OF THE TRUSTEES AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST AUGUST 2022
FOR
THE INTERNATIONAL CML FOUNDATION

Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE

THE INTERNATIONAL CML FOUNDATION

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST AUGUST 2022

	Page
Report of the Trustees	1 to 4
Independent Examiner's Report	5
Statement of Financial Activities	6
Balance Sheet	7
Notes to the Financial Statements	8 to 15

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST AUGUST 2022

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st August 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

The object of the Foundation is the advancement of health by the improvement of the treatment in all parts of the world of chronic myeloid leukaemia and related diseases (together "CML") and for the purpose of carrying out those general objects, the primary objects of the Foundation are in particular: -

- (i) to improve clinical practice and disease monitoring in the treatment of CML
- (ii) to support, encourage and promote research into the causes, prevention, study and treatment of CML
- (iii) to promote and support the education of and disseminate knowledge amongst clinicians, scientists, health professionals and patients in matters concerning CML
- (iv) to promote, foster and co-ordinate collaboration that is particularly (but not exclusively) international and is not only in the areas and activities of clinical practice disease monitoring and research into CML but also in any area or activity which is or may be conducive to the acceleration of the control and/or cure of CML
- (v) to promote, set up, establish and support and share and exchange knowledge with other organisations whose objects are similar to these general or primary objects
- (vi) to assist or promote any other charitable purposes which are related to these general and primary objects.

Significant activities

In furtherance of the objects, the Foundation has the following powers: -

- (i) to promote or carry out research
- (ii) to provide advice
- (iii) to give and exchange information and advice and promote learning, study and research
- (iv) to commission, publish, distribute and contribute to papers, books, periodicals, reports, leaflets, posters and other publications of any description
- (v) to hold, attend and sponsor conferences, meetings, lectures, exhibitions and discussions
- (vi) to raise funds and to apply for and solicit grants from pharmaceutical companies anywhere in the world.

Public benefit

The Trustees have considered their duty to have due regard to public benefit guidance published by the Commission and in their opinion, the foregoing report on the achievements and performance demonstrates that they have complied therewith.

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST AUGUST 2022

ACHIEVEMENT AND PERFORMANCE

Charitable activities

The iCMLf continued to lead the CML community with the COVID-19 & CML case collection, analysis and treatment guidance. There are 3 iCMLf international research projects underway. The online webinars continue for COVID guidance and other key areas of CML management. With the launch of the iCMLf Knowledge Centre, a new educational program specifically for non-academic centres, the iCMLf continues to be at the forefront of CML education and enhancing patient management around the world.

Global Research Programs

Covid-19 (CANDID) study - This remained a significant focus for the year. The completed dataset included 1,050 cases from 900 physicians in 58 countries. the data is widely respected with 4 further presentations at international conferences.

Cure Consortium

iCMLf Treatment Free Remission Alliance - Global TFR registry began in February 2022. 24 sites from 16 countries and 2.900 potential datasets. Site initiation remains ongoing.

iCMLf Genomic Alliance - The iCMLf genomics project 'Clonal Hierarchy in CML' data upload is underway. 12 sites from 10 countries participating.

Online CML Education

iCMLf Clinical Conversations - 9 discussions with 16 experts from 10 countries with over 300 live participants and 3,000 online participants.

iCMLf Knowledge Centre

The Knowledge Centre is an interactive, online resource providing educational content for holistic CML patient management. 33 speaker from 16 countries with 1,600 users.

FINANCIAL REVIEW

Financial position

The financial position of the International CML Foundation remains solid.

Principal funding sources

The iCMLf works closely with industry and community partners to secure unrestricted grants and sponsorship for our programs and activities. The iCMLf requests donations through the iCMLf website.

Reserves policy

The reserves at the year end were £328,540 (2021 - £305,347). It is the policy of the Trustees to maintain sufficient reserves to ensure the day to day running of the Foundation. The level of reserves and current financial commitments are reviewed regularly at Trustees' meetings. The Foundation plans to hold a minimum of £150,000 as reserve funding. This is the amount for the foundation to operate without further income/outgoings for one year.

FUTURE PLANS

While maintaining the expert best practice and education initiatives of the Foundation, we aim to harness global network of the iCMLf to enhance research into potential cures for CML. The iCMLf Genomics Alliance will access the wealth of genomic information that is generated in local CML research projects by facilitating data assimilation and samples exchanges through an international data collection platform. Combining many data sets and facilitating global collaborative studies will enable us to develop a baseline predictor of adverse outcomes.

The iCMLf TFR Alliance looks to define biomarkers for treatment discontinuation and a functional cure of CML.

The CML and COVID-19 retrospective case analysis will provide data for physicians to base treatment decisions on as the pandemic continues.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST AUGUST 2022

STRUCTURE, GOVERNANCE AND MANAGEMENT

Recruitment and appointment of new trustees

The power of appointing new or additional Trustees is vested in the existing Trustees. Prior to appointment, new Trustees would be introduced to the workings of the Foundation and advised of their responsibilities.

Organisational structure

The chief executive reports to the ten iCMLf Directors, specifically the iCMLf Chairman.

The operational team; Communications Director, Communications Manager, Digital Media Officer, and ERSAP Program Coordinator, report to the chief executive.

Strategic direction, financial review and budget approval are set at an annual iCMLf directors meeting in September/October each year. Further directors planning and discussion meetings are held quarterly.

Strategic planning is assisted with an annual advisors meeting. This includes the thirteen physicians, scientific and patient advisors and members from the 36 countries with iCMLf National Representatives.

The operational team meets every 6-8 weeks. The communications director/communications manager meet biweekly with the chief executive respectively and the program coordinator and chief executive meet weekly for business planning. The chief executive and iCMLf Chairman meet monthly.

Decisions are escalated from the operational team to the chief executive, iCMLf Chairman and iCMLf Board of Directors according to scale and impact.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number
06996068 (England and Wales)

Registered Charity number
1132984

Registered office
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE

Trustees

Professor T P Hughes
Professor M Baccarani Professor (resigned 20/12/2021)
Professor J Cortes Professor
Professor B Druker Professor
Professor A Hochhaus Professor
Professor J Radich Professor
Professor C Schiffer Professor
Professor J F Apperley DM FRCP/Path Professor
Professor M Mauro Professor
Professor G Saglio Professor

Company Secretary
Ms N C Evans

Independent Examiner
R Appleyard FCA
Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST AUGUST 2022

REFERENCE AND ADMINISTRATIVE DETAILS

Bankers

HSBC Bank, 152 Portobello Road, London, W11 2EA

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on 11th May 2023 and signed on its behalf by:

Professor T P Hughes - Trustee

Independent examiner's report to the trustees of The International CML Foundation ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st August 2022.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement - matters of concern identified

I have completed my examination.

I draw attention to Note 10 of the accounts, regarding the balance of funds held by Paypal. Whilst nothing has come to my attention to indicate that the balance shown in the accounts is incorrect, it has not been possible to verify the balance of funds held in the Paypal account as part of my examination due to the fact that the charity is currently unable to access the account.

I confirm that no other matters have come to my attention in connection with the examination giving me reasonable cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; and
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached.

R Appleyard FCA

Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE

16th May 2023

THE INTERNATIONAL CML FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31ST AUGUST 2022

	Notes	Unrestricted funds £	Restricted funds £	2022 Total funds £	2021 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies		119,414	66,043	185,457	75,107
Other trading activities	2	279	-	279	-
Other income	3	23,495	-	23,495	(5,904)
Total		<u>143,188</u>	<u>66,043</u>	<u>209,231</u>	<u>69,203</u>
EXPENDITURE ON					
Charitable activities					
Diagnosis & testing		-	11,784	11,784	-
Scientific meetings		5,926	-	5,926	696
ICMLF Forum		17	-	17	3,402
Communications		31,816	372	32,188	29,031
Fundraising		12,448	-	12,448	8,913
Cure Consortium		14,102	-	14,102	5,147
Candid		-	23,304	23,304	35,113
Knowledge Centre		(20,073)	61,138	41,065	21,529
Conversations		23,403	1,559	24,962	28,938
Other		20,242	-	20,242	13,891
Total		<u>87,881</u>	<u>98,157</u>	<u>186,038</u>	<u>146,660</u>
NET INCOME/(EXPENDITURE)		55,307	(32,114)	23,193	(77,457)
RECONCILIATION OF FUNDS					
Total funds brought forward		156,702	148,645	305,347	382,804
TOTAL FUNDS CARRIED FORWARD		<u>212,009</u>	<u>116,531</u>	<u>328,540</u>	<u>305,347</u>

The notes form part of these financial statements

BALANCE SHEET
31ST AUGUST 2022

	Notes	Unrestricted funds £	Restricted funds £	2022 Total funds £	2021 Total funds £
CURRENT ASSETS					
Debtors	10	102,793	-	102,793	86,793
Cash at bank and in hand		113,584	116,531	230,115	222,826
		<u>216,377</u>	<u>116,531</u>	<u>332,908</u>	<u>309,619</u>
CREDITORS					
Amounts falling due within one year	11	(4,368)	-	(4,368)	(4,272)
		<u>212,009</u>	<u>116,531</u>	<u>328,540</u>	<u>305,347</u>
NET CURRENT ASSETS					
		<u>212,009</u>	<u>116,531</u>	<u>328,540</u>	<u>305,347</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		212,009	116,531	328,540	305,347
		<u>212,009</u>	<u>116,531</u>	<u>328,540</u>	<u>305,347</u>
NET ASSETS		<u>212,009</u>	<u>116,531</u>	<u>328,540</u>	<u>305,347</u>
FUNDS	12				
Unrestricted funds				212,009	156,702
Restricted funds				116,531	148,645
TOTAL FUNDS				<u>328,540</u>	<u>305,347</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st August 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st August 2022 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 11th May 2023 and were signed on its behalf by:

T P Hughes - Trustee

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

Items of income are recognised and included in the accounts when all of the following criteria are met:

- The charity or its subsidiary have entitlement to the funds;
- any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity or its subsidiary;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Debtors

Debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid after taking account of any trade discounts due.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result and are shown as other income.

2. OTHER TRADING ACTIVITIES

The iCMLf request donations through the iCMLf website.

3. OTHER INCOME

Other income consists of the profit on foreign currency exchange in accordance with the accounting policy on foreign exchange transactions.

4. SUPPORT COSTS

	Management fees £	Finance £	Other £	Governance costs £	Totals £
Other resources expended	17,586	268	567	1,821	20,242
Diagnosis & testing	11,784	-	-	-	11,784
Scientific meetings	1,785	-	-	-	1,785
Communications	27,990	-	-	1,456	29,446
Fundraising	5,034	17	1,966	-	7,017
Cure Consortium	10,926	-	-	-	10,926
Candid	22,403	-	-	-	22,403
Knowledge Centre	36,736	-	-	1,456	38,192
Conversations	23,501	-	-	1,456	24,957
	<u>157,745</u>	<u>285</u>	<u>2,533</u>	<u>6,189</u>	<u>166,752</u>

Support costs, included in the above, are as follows:

Management fees

	Other resources expended £	Diagnosis & testing £	Scientific meetings £
Management & admin	<u>17,586</u>	<u>11,784</u>	<u>1,785</u>
	Communications £	Fundraising £	Cure Consortium £
Management & admin	<u>27,990</u>	<u>5,034</u>	<u>10,926</u>
	Knowledge Centre £	Conversations £	2022 Total activities £
Management & admin	<u>36,736</u>	<u>23,501</u>	<u>157,745</u>
			2021 Total activities £
			<u>132,913</u>

4. SUPPORT COSTS - continued
Finance

			2022	2021
	Other resources expended £	Fundraising £	Total activities £	Total activities £
Bank charges	<u>268</u>	<u>17</u>	<u>285</u>	<u>395</u>
Other				

			2022	2021
	Other resources expended £	Fundraising £	Total activities £	Total activities £
Sundry office costs	<u>567</u>	<u>1,966</u>	<u>2,533</u>	<u>2,631</u>
Governance costs				

	Other resources expended £	Communications £	Knowledge Centre £
Accountancy - Independent examination fee	-	1,456	1,456
Legal and Professional fees	<u>1,821</u>	<u>-</u>	<u>-</u>
	<u>1,821</u>	<u>1,456</u>	<u>1,456</u>

		2022 Total activities £	2021 Total activities £
	Conversations £		
Accountancy - Independent examination fee	1,456	4,368	4,242
Legal and Professional fees	<u>-</u>	<u>1,821</u>	<u>-</u>
	<u>1,456</u>	<u>6,189</u>	<u>4,242</u>

5. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2022 £	2021 £
Accountancy - Independent examination fee	<u>4,368</u>	<u>4,242</u>

6. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31st August 2022 nor for the year ended 31st August 2021.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31st August 2022 nor for the year ended 31st August 2021.

7. STAFF COSTS

The average monthly number of employees during the year was as follows:

	2022	2021
Charitable activities	<u>4</u>	<u>4</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2022	2021
£80,001 - £90,000	<u>1</u>	<u>1</u>

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	8,459	66,648	75,107
Other income	<u>(5,904)</u>	<u>-</u>	<u>(5,904)</u>
Total	<u>2,555</u>	<u>66,648</u>	<u>69,203</u>
EXPENDITURE ON			
Charitable activities			
Scientific meetings	696	-	696
ICMLF Forum	3,402	-	3,402
Communications	1,414	27,617	29,031
Fundraising	5,818	3,095	8,913
Cure Consortium	-	5,147	5,147
Candid	39	35,074	35,113
Knowledge Centre	21,529	-	21,529
Conversations	27,098	1,840	28,938
Other	<u>13,891</u>	<u>-</u>	<u>13,891</u>
Total	<u>73,887</u>	<u>72,773</u>	<u>146,660</u>
NET INCOME/(EXPENDITURE)	(71,332)	(6,125)	(77,457)
RECONCILIATION OF FUNDS			
Total funds brought forward	228,033	154,771	382,804

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued

	Unrestricted funds £	Restricted funds £	Total funds £
TOTAL FUNDS CARRIED FORWARD	<u>156,701</u>	<u>148,646</u>	<u>305,347</u>

9. VOLUNTEERS

The charity heavily relies upon the many medical professionals who donate their time to help run the various charitable activities undertaken. It is not possible to accurately calculate the value of the services contributed by these volunteers and therefore the numbers do not reflect either the income or expenditure, however it is thought to be in the region of £230,000.

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022 £	2021 £
Other debtors	<u>102,793</u>	<u>86,793</u>

Included within other debtors is a balance of £88,015 in respect of funds held by Paypal. As a result of a change of personnel, the account access is being transferred by Paypal, and until this process has been completed the charity cannot transfer or use these funds.

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022 £	2021 £
Accrued expenses	<u>4,368</u>	<u>4,272</u>

12. MOVEMENT IN FUNDS

	At 1/9/21 £	Net movement in funds £	At 31/8/22 £
Unrestricted funds			
General fund	156,702	55,307	212,009
Restricted funds			
Novartis Pharmaceuticals Corporation	123,410	(11,784)	111,626
Pfizer	24,863	(24,863)	-
Novartis Patient	372	(372)	-
Novartis Pharma AG	-	4,905	4,905
	<u>148,645</u>	<u>(32,114)</u>	<u>116,531</u>
TOTAL FUNDS	<u>305,347</u>	<u>23,193</u>	<u>328,540</u>

12. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	143,188	(87,881)	55,307
Restricted funds			
Novartis Pharmaceuticals Corporation	-	(11,784)	(11,784)
Pfizer	-	(24,863)	(24,863)
Novartis Patient	-	(372)	(372)
Novartis Pharma AG	66,043	(61,138)	4,905
	<u>66,043</u>	<u>(98,157)</u>	<u>(32,114)</u>
TOTAL FUNDS	<u>209,231</u>	<u>(186,038)</u>	<u>23,193</u>

Comparatives for movement in funds

	At 1/9/20 £	Net movement in funds £	At 31/8/21 £
Unrestricted funds			
General fund	224,118	(67,416)	156,702
Cepheid	3,915	(3,915)	-
	<u>228,033</u>	<u>(71,331)</u>	<u>156,702</u>
Restricted funds			
Novartis Pharmaceuticals Corporation	123,410	-	123,410
Pfizer	23,118	1,745	24,863
Novartis Killi Climb	8,243	(8,243)	-
Novartis Patient	-	372	372
	<u>154,771</u>	<u>(6,126)</u>	<u>148,645</u>
TOTAL FUNDS	<u>382,804</u>	<u>(77,457)</u>	<u>305,347</u>

12. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	2,555	(69,971)	(67,416)
Cepheid	-	(3,915)	(3,915)
	<u>2,555</u>	<u>(73,886)</u>	<u>(71,331)</u>
Restricted funds			
Takeda Oncology	29,457	(29,457)	-
Pfizer	36,819	(35,074)	1,745
Novartis Killi Climb	-	(8,243)	(8,243)
Novartis Patient	372	-	372
	<u>66,648</u>	<u>(72,774)</u>	<u>(6,126)</u>
TOTAL FUNDS	<u><u>69,203</u></u>	<u><u>(146,660)</u></u>	<u><u>(77,457)</u></u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1/9/20 £	Net movement in funds £	At 31/8/22 £
Unrestricted funds			
General fund	224,118	(12,109)	212,009
Cepheid	3,915	(3,915)	-
	<u>228,033</u>	<u>(16,024)</u>	<u>212,009</u>
Restricted funds			
Novartis Pharmaceuticals Corporation	123,410	(11,784)	111,626
Pfizer	23,118	(23,118)	-
Novartis Killi Climb	8,243	(8,243)	-
Novartis Pharma AG	-	4,905	4,905
	<u>154,771</u>	<u>(38,240)</u>	<u>116,531</u>
TOTAL FUNDS	<u><u>382,804</u></u>	<u><u>(54,264)</u></u>	<u><u>328,540</u></u>

12. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	145,743	(157,852)	(12,109)
Cepheid	-	(3,915)	(3,915)
	<u>145,743</u>	<u>(161,767)</u>	<u>(16,024)</u>
Restricted funds			
Novartis Pharmaceuticals Corporation	-	(11,784)	(11,784)
Takeda Oncology	29,457	(29,457)	-
Pfizer	36,819	(59,937)	(23,118)
Novartis Killi Climb	-	(8,243)	(8,243)
Novartis Patient	372	(372)	-
Novartis Pharma AG	66,043	(61,138)	4,905
	<u>132,691</u>	<u>(170,931)</u>	<u>(38,240)</u>
TOTAL FUNDS	<u>278,434</u>	<u>(332,698)</u>	<u>(54,264)</u>

13. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31st August 2022.